LONDON (ShareCast) - (Sharecast News) - 4basebio said on Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial using an mRNA therapy developed with the company's proprietary 'opDNA' synthetic DNA template, marking what it called a major milestone for the technology's adoption in advanced genetic medicines.
The AIM-traded firm said the trial followed FDA approval of the partner's investigational new drug application.

4basebio, which signed a supply agreement with the unnamed company last April, said specific trial details remained confidential.

The opDNA template is one of four application-specific DNA products developed by the Cambridge-based biotech, supporting mRNA in-vitro transcription processes while offering cost, purity and production advantages over conventional plasmid DNA.

The company said the achievement followed GMP certification of its late-phase manufacturing facility by the UK Medicines and Healthcare products Regulatory Agency (MGRA) in April.

Together, the developments "underscore 4basebio's role as a trusted partner to the global biopharma industry," the company said, highlighting the growing use of synthetic DNA in cell and gene therapies.

"We are delighted to have supported this leading pharmaceutical innovator in their recent IND filing and start of their patient dosing trials," said chief executive Dr Heikki Lanckriet.

"This represents another major regulatory milestone for 4basebio and a clear signal of growing industry adoption of synthetic DNA in the use of cell and gene therapies and vaccines.

"We are excited to see increasing momentum as a growing number of client programs advance into the clinic."

At 1108 GMT, shares in 4basebio were up 10.34% at 800p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE